Exciting Developments in LBL-024 for Advanced Cancer Treatment
Nanjing Leads Biolabs Co., Ltd. has recently unveiled remarkable clinical findings from a multicenter phase Ib/II trial. This trial focuses on LBL-024, an innovative anti-PD-L1/4-1BB bispecific antibody, combined with etoposide and platinum-based chemotherapy for patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC), marking a significant step forward in oncology.
Highlights from the ASCO Annual Meeting
The prestigious American Society of Clinical Oncology (ASCO) Annual Meeting serves as a leading platform for showcasing transformative advancements in cancer research. In 2025, a record-breaking number of submissions were made, with 32 studies from China being selected for oral presentations. Among these was the trial for LBL-024, highlighting its critical importance in advancing cancer therapies.
Study Results Show Compelling Efficacy
The trial's findings reveal that in a cohort of 52 efficacy-evaluable patients, LBL-024 displayed an impressive overall response rate (ORR) of 75% and a disease control rate (DCR) of 92.3%. These results substantially exceed historical ORR data, which typically ranges from 30% to 55% with standard chemotherapy treatments.
Promising Outcomes with Optimal Dosing
Notably, the 15 mg/kg dose optimization demonstrated the highest anti-tumor efficacy, achieving an ORR of 83.3% along with a 100% DCR. Furthermore, an impressive 57.7% of patients experienced tumor shrinkage exceeding 50%. As of a specific follow-up period, the progression-free survival (PFS) data indicated favorable durability trends across all dosing groups.
Insights from Leadership
Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, expressed enthusiasm about these clinical results, stating, "We are excited to share this critical data, supporting the progression of LBL-024 into a pivotal phase III trial for EP-NEC. Our focus on efficient development through registrational trials in underserved areas aligns with maximizing therapeutic impact across broader indications. LBL-024's significance in first-line treatments highlights our commitment to providing innovative options for patients globally."
Dedication to Innovation
Dr. Xiaoqiang Kang, Founder and CEO of Leads Biolabs, passionately remarked on the importance of LBL-024's recognition at ASCO. He emphasized that the company’s R&D approach prioritizes unique innovation to tackle substantial clinical challenges, positioning LBL-024 as a crucial advancement in oncology treatment.
About LBL-024
LBL-024 stands as a potential first-in-class bispecific antibody, targeting PD-L1 and co-stimulatory receptor 4-1BB. It represents the first 4-1BB-targeting bispecific antibody to reach pivotal trial status globally, aiming to address a significant gap in treatments for EP-NEC.
Revolutionary Design and Efficacy
Leveraging the X-Body™ bispecific platform developed by Leads Biolabs, LBL-024 features an advanced design with two binding domains for both PD-L1 and 4-1BB, which promotes immune system activation against tumors. Phase I/II trials have shown favorable safety profiles and promising efficacy, confirming the urgent need for this treatment in the absence of a standard care for EP-NEC.
The Future of Cancer Treatment
In recognition of its potential, LBL-024 received Breakthrough Therapy Designation from the National Medical Products Administration in China and Orphan Drug Designation from the FDA for neuroendocrine carcinoma. Its efficacy extends beyond EP-NEC, showing hope in treating other malignancies, including small cell lung cancer and ovarian cancer.
About Leads Biolabs
Leads Biolabs, founded in 2012, focuses on developing innovative therapies to meet urgent medical needs in oncology and other severe diseases globally. With a rich pipeline of 12 drug candidates, including potential treatments for various cancer types, Leads Biolabs is leading advancements in next-generation immuno-oncology.
Frequently Asked Questions
What is LBL-024?
LBL-024 is a novel bispecific antibody targeting PD-L1 and 4-1BB, under development as a treatment for advanced neuroendocrine carcinoma.
What were the results of the ASCO presentation?
The ASCO presentation highlighted a 75% overall response rate and a 92.3% disease control rate in patients treated with LBL-024 combined with chemotherapy.
Who is leading the clinical study?
The study is spearheaded by Professor Shen Lin from Peking University Cancer Hospital across multiple clinical sites.
What distinguishes LBL-024 from other therapies?
LBL-024 uniquely addresses PD-L1 and 4-1BB simultaneously, enhancing immune response significantly compared to traditional therapies.
What future developments are planned for LBL-024?
There are plans for initiating pivotal phase III trials and exploring its effectiveness across other cancer types and indications.
